Markets
BSE See NSE See 39,046.34
85.55 (0.22%)
collapse Related Readings collapse

Dr Reddy’s Laboratories: Recommendation Review

| 9/6/2012 9:00 PM Thursday

We had analysed Dr Reddy’s Laboratories (DRL) in DSIJ Vol. 27, Issue No. 7 (dated 25th March, 2012). By 20th April, 2012, the scrip was trading up eight per cent at Rs 1818. From then on, however, it has come off significantly. At a CMP of Rs 1690, it has traded flat and has failed to perform as per our expectations. The scrip has recently found its place back in the Sensex. After our recommendation, investors have also pocketed a dividend of Rs 13.72, yielding 0.8 per cent on their purchase price.

We had recommended the stock based on the USFDA-approved product pipeline as well as the potential FTFs that the company would be monetising. DRL is a dominant pharma player in the overseas markets, garnering 80 per cent of its revenues through exports. Another factor that made us recommend the stock was the fact that the upcoming product launches are likely to have a favourable impact on its revenues.

In the last two quarters (March 2012 and June 2012), the growth in the company’s revenues was around 30 per cent. The net profit in the March quarter grew by 38 per cent while that in the June quarter grew by 28 per cent, which was below expectations. The EBITDA margins in June 2012 have shown a sequential decline due to pricing pressures.

In the past few months, the company has made some positive announcements that are expected to help the business grow further. It has tied up with Merck Serono to develop and commercialise biosimilar compounds in the oncology segment. Besides, the USFDA has lifted the import alert on DRL’s manufacturing facility in Mexico. The company has recently launched Lipitor in the diluted market and will also monetise some of its FTFs this year. Based on this, we advise our readers to hold the stock with a price target of Rs 1900.

 

Find More Articles on: DSIJ Magazine, Reviews, Stock Recommendations, Fundamental Picks, Product, Large Cap

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

DSIJ Mindshare

MIDHANI and HAL partner to develop bio implants

Geyatee Deshpande / Article rating: 5.0

Mishra Dhatu Nigam Limited (MIDHANI) signs an MoU with Hindustan Antibiotics Limited (HAL). This MoU will provide synergy for quality manufacturing of MIDHANI’s Bio-medical Implants and get access to the pan-India distribution of HAL. This partnership is aimed to gain advantage from the strengths of both the companies and benefit users of Bio-medical products in India.

12345678910Last

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Logistics sector will play a vital role in making the concept of ‘Make in India’ a success. This will be further aided by some of the recent steps taken by Government of India such as granting of infra sector status to logistics sector.

Best and worst Performing Sector Funds of Year 2017

Best and worst Performing Sector Funds of Year 2017

As the year-end has approached most of you are eager to know the mutual fund movers and shakers of the year 2017. Read on to find the performance of various sector dedicated funds.

Markets may start positive, but volatility likely due to F&O expiry

Markets may start positive, but volatility likely due to F&O expiry

The start of the F&O expiry day is likely to be in the green, but volatility may creep in with the progress of the session. The SGX Nifty suggests that the Nifty could open at 10,525 with gains of 32 points at the opening bell. 

Pidilite announces buyback of Rs 500 crore

Pidilite announces buyback of Rs 500 crore

The buyback offer comprises purchase of up to 50,00,000 equity shares. The buyback offer size comprises 0.975 per cent of the total paid-up equity capital of the company.

Bank Nifty drags markets to close in the red

Bank Nifty drags markets to close in the red

The late session fall in Bank Nifty changed the direction of the market, leading to a marginal fall in the benchmark indices. Bank Nifty yet again resisted at its multiple point downward sloping trendline level at 25733.

Six major underperforming MF schemes having higher expense ratios

Six major underperforming MF schemes having higher expense ratios

Mutual funds with a large size of assets under management (AUMs) are supposed to have lower expense ratios. However, there are schemes with large AUMs but having higher expense ratios and generating lower returns. 

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma index has come in as the healer in an otherwise sluggish market. Index has given a consolidation breakout at the 9420 level today and if the it sustains 9420, followed by 9628 on the upside, it has a long way to go.

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.35 p.m. on December 27.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on December 27 opened gap down. BSE Sensex is trading at 34,068.15, up by 57.54 points and the Nifty is trading at 10,539.45, up by 7.95 points.

Five stocks with selling interest

Five stocks with selling interest

Overall volumes in futures & options currently stand at 62.75 lakh contracts with a turnover of Rs. 5,19,204.72 crore.